Skip to content
10-Q

Quarterly Report

BIOREGENX, INC. BRGX

0001683168-24-007026

← back to feed
Filed
Oct 9, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Sep 18, 2024 956.53M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $57.4K
Cash And Equivalents Q2 2024 · Dec 31, 2023 $125.4K
Current Liabilities Q2 2024 · Jun 30, 2024 $3.42M
Current Liabilities Q2 2024 · Dec 31, 2023 $2.79M
Total Liabilities Q2 2024 · Jun 30, 2024 $3.67M
Total Liabilities Q2 2024 · Dec 31, 2023 $2.94M
Current Assets Q2 2024 · Jun 30, 2024 $326.08K
Current Assets Q2 2024 · Dec 31, 2023 $652.66K
Total Assets Q2 2024 · Jun 30, 2024 $17.89M
Total Assets Q2 2024 · Dec 31, 2023 $865.75K
Shares Diluted restated Q2 2024 · Jun 30, 2023 764.3M sh
Shares Diluted restated Q2 2024 · Jun 30, 2023 762.01M sh
Capex Q2 2024 · Jun 30, 2023 $0
Operating Cash Flow restated Q2 2024 · Jun 30, 2023 −$985.95K
Stockholders Equity restated Q2 2024 · Jun 30, 2023 −$2.58M
Stockholders Equity restated Q2 2024 · Mar 31, 2023 −$2.42M
Stockholders Equity restated Q2 2024 · Dec 31, 2022 −$2.53M
Eps Diluted Q2 2024 · Jun 30, 2023 $0.00
Eps Diluted Q2 2024 · Jun 30, 2023 $0.00
Eps Basic Q2 2024 · Jun 30, 2023 $0.00
Eps Basic Q2 2024 · Jun 30, 2023 $0.00
Sga Expense Q2 2024 · Jun 30, 2023 $1M
Sga Expense Q2 2024 · Jun 30, 2023 $1.77M
Rd Expense Q2 2024 · Jun 30, 2023 $80.78K
Rd Expense Q2 2024 · Jun 30, 2023 $175.07K
Net Income restated Q2 2024 · Jun 30, 2023 −$594.46K
Net Income restated Q2 2024 · Jun 30, 2023 −$824.3K
Operating Income restated Q2 2024 · Jun 30, 2023 −$544.62K
Operating Income restated Q2 2024 · Jun 30, 2023 −$728.73K
Gross Profit Q2 2024 · Jun 30, 2023 $598.31K
Gross Profit Q2 2024 · Jun 30, 2023 $1.36M
Cost Of Revenue Q2 2024 · Jun 30, 2023 $264.97K
Cost Of Revenue Q2 2024 · Jun 30, 2023 $576.66K
Revenue restated Q2 2024 · Jun 30, 2023 $863.28K
Revenue restated Q2 2024 · Jun 30, 2023 $1.94M